• Simris Group entered a new memorandum of understanding in October 2026 for Immunrise Biocontrol France to lease, then acquire, its Hammenhög facility.
• The agreement covers the industrial site and related assets; completion remains subject to financing and definitive agreements.
• The planned divestment would reduce operational commitments to the facility, allowing resources to focus on Simris Biologics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simris Group AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.